Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex)

Jessica Ong; Nishant Hemanth Davidoss; Anant Bhosale; Chandrakumar Balaratnasingam

doi:10.1136/bcr-2020-235102

Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex)

Jessica Ong, Nishant Hemanth Davidoss, Anant Bhosale, Chandrakumar Balaratnasingam

Research output: Contribution to journal › Article › peer-review

Abstract

A 59-year-old man with diabetic macular oedema was treated with a dexamethasone intravitreal implant (Ozurdex) to his right eye. Immediately after injection, the implant was noted to have extruded into the perilimbal subconjunctival space. The remnants of the implant were expeditiously removed the following day to avoid corneal decompensation and permanent corneal oedema. Endothelial decompensation secondary to the migration of dexamethasone implants into the subconjunctival space or anterior chamber is a recognised complication of Ozurdex injection. The patient recovered well postoperatively with no further complications. He was planned for a new Ozurdex implant 1 month later.

Original language	English
Article number	e235102
Journal	BMJ Case Reports
Volume	13
Issue number	11
DOIs	https://doi.org/10.1136/bcr-2020-235102
Publication status	Published - 3 Nov 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bcr-2020-235102

Cite this

@article{5e9cf98281e943daa4767e7d2800fda7,

title = "Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex)",

abstract = "A 59-year-old man with diabetic macular oedema was treated with a dexamethasone intravitreal implant (Ozurdex) to his right eye. Immediately after injection, the implant was noted to have extruded into the perilimbal subconjunctival space. The remnants of the implant were expeditiously removed the following day to avoid corneal decompensation and permanent corneal oedema. Endothelial decompensation secondary to the migration of dexamethasone implants into the subconjunctival space or anterior chamber is a recognised complication of Ozurdex injection. The patient recovered well postoperatively with no further complications. He was planned for a new Ozurdex implant 1 month later.",

keywords = "Anterior Chamber, Dexamethasone/administration & dosage, Drug Implants/adverse effects, Foreign-Body Migration/diagnosis, Glucocorticoids/administration & dosage, Humans, Intravitreal Injections, Macular Edema/drug therapy, Male, Middle Aged",

author = "Jessica Ong and Davidoss, {Nishant Hemanth} and Anant Bhosale and Chandrakumar Balaratnasingam",

note = "{\textcopyright} BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2020",

month = nov,

day = "3",

doi = "10.1136/bcr-2020-235102",

language = "English",

volume = "13",

journal = "B.M.J. Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

number = "11",

}

TY - JOUR

T1 - Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex)

AU - Ong, Jessica

AU - Davidoss, Nishant Hemanth

AU - Bhosale, Anant

AU - Balaratnasingam, Chandrakumar

N1 - © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/11/3

Y1 - 2020/11/3

N2 - A 59-year-old man with diabetic macular oedema was treated with a dexamethasone intravitreal implant (Ozurdex) to his right eye. Immediately after injection, the implant was noted to have extruded into the perilimbal subconjunctival space. The remnants of the implant were expeditiously removed the following day to avoid corneal decompensation and permanent corneal oedema. Endothelial decompensation secondary to the migration of dexamethasone implants into the subconjunctival space or anterior chamber is a recognised complication of Ozurdex injection. The patient recovered well postoperatively with no further complications. He was planned for a new Ozurdex implant 1 month later.

AB - A 59-year-old man with diabetic macular oedema was treated with a dexamethasone intravitreal implant (Ozurdex) to his right eye. Immediately after injection, the implant was noted to have extruded into the perilimbal subconjunctival space. The remnants of the implant were expeditiously removed the following day to avoid corneal decompensation and permanent corneal oedema. Endothelial decompensation secondary to the migration of dexamethasone implants into the subconjunctival space or anterior chamber is a recognised complication of Ozurdex injection. The patient recovered well postoperatively with no further complications. He was planned for a new Ozurdex implant 1 month later.

KW - Anterior Chamber

KW - Dexamethasone/administration & dosage

KW - Drug Implants/adverse effects

KW - Foreign-Body Migration/diagnosis

KW - Glucocorticoids/administration & dosage

KW - Humans

KW - Intravitreal Injections

KW - Macular Edema/drug therapy

KW - Male

KW - Middle Aged

UR - http://www.scopus.com/inward/record.url?scp=85095675121&partnerID=8YFLogxK

UR - https://casereports.bmj.com/content/13/11/e235102

U2 - 10.1136/bcr-2020-235102

DO - 10.1136/bcr-2020-235102

M3 - Article

C2 - 33148568

VL - 13

JO - B.M.J. Case Reports

JF - B.M.J. Case Reports

SN - 1757-790X

IS - 11

M1 - e235102

ER -

Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this